You just read:

BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS)

News provided by

BrainStorm Cell Therapeutics Inc.

Jul 18, 2016, 08:00 ET